Project description
A multi-organ-on-chip platform that emulates circadian rhythms enhances compound testing
Testing the safety and efficacy of compounds including pharmaceuticals, foods and cosmetics has conventionally relied on animal models. Aside from the inadequate extrapolation of results to humans, increased regulation is pushing companies to find alternative solutions. The Israeli SME Tissue Dynamics is pushing the frontiers of organ-on-chip technologies with a multi-organ-on-chip platform that not only allows real-time sensing of tissue function in four organs at once but also incorporates circadian rhythms that will enhance optimisation of timing and dosage. The EU-funded mP-CSE project is helping the team optimise the technology, significantly reducing development time and cost for companies while enhancing the effectiveness and safety of future formulations.
Objective
Tissue Dynamics Ltd. is a groundbreaking biotechnology company focused on developing smart microphysiological platform technologies for drug, food, and cosmetic development. Pharmaceutical and cosmetic companies face huge costs of developing and testing new products (an average of €2.5B to develop a single drug), which is increasing over the years. Traditionally, these tests have been carried out in animal models whose limitations in predicting human responses are significant (70% of drugs toxic to humans are not toxic to animals). These limitations lead to the withdrawal of many drugs in the market, making drug development a costly risky process. Organ-on-chip platforms, developed in recent years, have proven to be a better alternative to current laboratory models, offering more physiological and similar characteristics to the human body. Tissue Dynamics goal is to provide a functionally scaled Multi Organ-on-Chip (MOC) platform that uses real-time sensing of tissue function to detect the effect of drug-induced physiological stress in multiple 3D vascular organs (liver, heart, brain, kidney). Our latest innovation has been the incorporation of factors that mimic circadian rhythms in the organs, which is essential to test the physiological impact of the compounds tested. On the other hand, the incorporation of the circadian rhythm in our chips enhances the development of treatment schemes, adjusting in a more precise way the dose and the time of administration of the medications, seeking the maximum efficacy of them. The global Organ-on-Chip market is a rapidly-growing, estimated to reach $6.13 Billion by 2025, with an expected growth rate of CAGR 69.4%. Our platform will reduce the cost of new drugs development ultimately, helping patients by making more safe and effective medicines reach the market. In turn we expect ROI of 5 after five years of commercialization and hire 10 new employees.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health sciencesbasic medicinepharmacology and pharmacydrug safety
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- engineering and technologyother engineering and technologiesmicrotechnologyorgan on a chip
You need to log in or register to use this function
Programme(s)
Funding Scheme
SME-1 - SME instrument phase 1Coordinator
91904 JERUSALEM
Israel
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.